Core Viewpoint - NewGenIvf Group Limited has terminated its binding term sheet with European Wellness Investment Holdings Limited regarding a proposed reverse merger due to EWIHL's failure to deliver required draft audited financial statements by the deadline [1][2]. Company Overview - NewGen is a comprehensive fertility services provider in Asia, offering a range of fertility treatments to couples and individuals facing infertility challenges [4]. - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, providing services such as assisted reproductive technology, egg and sperm donation, and surrogacy [4]. Transaction Details - The proposed reverse merger would have resulted in EWIHL holding approximately 61.6% of NewGen's equity [2]. - The completion of the merger was contingent upon due diligence, delivery of draft audited financials for 2023 and 2024, and negotiation of a definitive agreement [2]. Management Commentary - The CEO of NewGen expressed confidence in the company's ability to pursue other growth opportunities despite the termination of the merger [3]. - The management team remains focused on executing the core business strategy and exploring avenues to create shareholder value, including recent acquisitions and services like lifetime egg-freezing [3].

Core Viewpoint - NewGenIvf Group Limited is progressing with a proposed reverse merger with European Wellness Investment Holdings Limited, while also completing the acquisition of MicroSort Reproductive Technology, indicating a strategic focus on growth and expansion in the fertility services sector in Asia [1][2][3]. Group 1: Reverse Merger with EWIHL - The proposed reverse merger with EWIHL would result in EWIHL holding approximately 61.6% of NewGen's equity upon completion [2]. - Completion of the merger is contingent upon due diligence, delivery of draft audited financials for 2023 and 2024 by March 31, 2025, and negotiation of a definitive agreement [2]. - As of the press release date, EWIHL has not provided the required draft financials, and key due diligence documents are still pending, which may delay the transaction [2]. Group 2: Acquisition of MicroSort Reproductive Technology - NewGen completed its acquisition of MicroSort Reproductive Technology on February 28, 2025, following a definitive agreement announced on January 21, 2025 [3]. - The company aims to continue evaluating strategic acquisition opportunities that align with its long-term growth strategy [3]. Group 3: Financial Performance and Position - The company has improved its financial standing from a deficit of $7 million to a surplus of over $10 million within five months, achieving a net asset increase of $17 million [4]. - As of February 28, the net asset value per share is reported at $2.16, with only $50,000 in debt on the balance sheet, positioning the company strongly for future strategic opportunities [4]. Group 4: Company Overview - NewGen is a comprehensive fertility services provider in Asia, offering a range of treatments including assisted reproductive technology, egg and sperm donation, and surrogacy [5]. - The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, focusing on increasing access to infertility treatments for couples and individuals [5].